ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541

Hisse Senetlerindeki Sıralama #19026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Hisse Fiyatı
$0.40104873
Piyasa Değeri
$168.05M
Değişim (1 gün)
5.56%
Değişim (1 yıl)
-70.06%
Ülke
CN
Ticaret ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)

Kategori

Healthcare
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) için hisse bölünme geçmişi
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. hissesi (sembol: 1541) toplamda 0 hisse bölünmesi yaşamıştır.
En son hisse bölünmesi Oct 21, 2026 tarihinde gerçekleşmiştir.
Oct 21, 2026 tarihinden önce alınan bir 1541 hissesi bugün 0 1541 hissesine eşdeğerdir.
Hisse bölünme listesi
Yıl Bölünme Çarpan Kümülatif Çarpan
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için hisse bölünmeleri
Şirket Hisse bölünme sayısı Kümülatif Çarpan Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL